ARTO trial (NCT03449719): Long-term overall survival analysis from a randomized phase II trial testing the benefit of stereotactic body radiotherapy addition to abiraterone acetate in oligometastatic ...

We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...

Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...

Backed by the venture portions of Eli Lily and Eisai, Excalipoint will look to progress the development of its six-strong TCE ...

Please provide your email address to receive an email when new articles are posted on . MADRID — A novel T-cell engager appeared safe and exhibited efficacy as treatment for neuroendocrine tumors, ...

DUBLIN--(BUSINESS WIRE)--The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. Delta-like ...

Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ...

Excalipoint Therapeutics will use its seed money to advance a pipeline of cancer therapies, including a tri-specific antibody ...

DUBLIN--(BUSINESS WIRE)--The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. Global DLL3 Targeted ...

BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer drug Imdelltra for up to $950 million. Royalty Pharma will pay BeOne $885 million upfront for certain royalty payments ...